In Silico‐Enabled Discovery and Development of Potent and Selective CDK11 Inhibitors
ChemMedChem · 27.03.2026 · 21 (6)
DOI: 10.1002/cmdc.202500882 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 26.03.2026. Verfasst von Frankie S Mak und 35 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Drug Development Centre (EDDC), Chromos, Singapore. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinases, Protein Kinase Inhibitors, Drug Design, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Experimental Drug Development Centre, Singapore.
Abstract (Originalsprache)
Cyclin‐dependent kinase 11 (CDK11) plays a critical role in cell cycle regulation and transcriptional control, making it a promising target for therapeutic intervention in cancer and other proliferative disorders. This study employs computationally driven approaches encompassing homology modelling, molecular dynamic simulations, ultralarge‐scale virtual screening and medicinal chemistry optimisation to develop a series of novel inhibitors of CDK11. Our virtual screening pipeline led to the identification of two initial hits (compounds 3 and 4 ), which were further evaluated through structure–activity relationship (SAR) studies. Together with structure‐guided molecular docking and design, these SAR analyses revealed key structural motifs and functional groups that are crucial for inhibitory activity and selectivity, providing insights into the efficient hit‐to‐lead optimisation. Compound 37 emerged as an optimised potent and selective CDK11 inhibitor (IC 50 4 nM, kinome panel clean). In a lung tumour model, mice dosed twice daily with 100 mg/kg of compound 37 showed ∼30% tumour growth inhibition. Both in vitro absorption, distribution, metabolism and excretion and in vivo mouse pharmacokinetics (PK) profiling indicated that compound 37 possesses excellent PK/pharmacodynamic properties, positioning the compound for further development and evaluation as a lead candidate for CDK11‐targeted therapy. Meanwhile, the series of compounds developed throughout this study represent novel tools for studying CDK11‐mediated pathophysiology. The integration of in silico modelling, screening and structure‐based drug design provides a robust strategy for accelerating the identification of potent and selective inhibitors for other CDK families.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Experimental Drug Development Centre (EDDC), Chromos, Singapore.
ORCID-Profile: Weijun Xu
Förderung
- Experimental Drug Development Centre, Singapore
Zitieren
APA
Mak, F. S., Ng, F. M., Anbazhagan, P., Madan, V., Tan, Q. W., See, Y., Lim, D., Kusuma, F. K., Toh, H., Mohammad, J., Yang, H., Sim, S., Tan, L. H., Tay, E., Hai, R. T. K., Kwek, P. Z., Wong, M. Y., Raman, D., Ang, Q. A., …, & Xu, W. (2026). In Silico‐Enabled Discovery and Development of Potent and Selective CDK11 Inhibitors. ChemMedChem, 21(6). https://doi.org/10.1002/cmdc.202500882
Vancouver
Mak FS, Ng FM, Anbazhagan P, Madan V, Tan QW, See Y, et al. In Silico‐Enabled Discovery and Development of Potent and Selective CDK11 Inhibitors. ChemMedChem. 2026;21(6). doi:10.1002/cmdc.202500882
BibTeX
@article{Mak2026,
author = {Mak, Frankie S and Ng, Fui Mee and Anbazhagan, Padmanabhan and Madan, Vikas and Tan, Qian Wen and See, Yiyang and Lim, Diane and Kusuma, Frances Karla and Toh, Hannah and Mohammad, Juliana and Yang, Haiyan and Sim, Sandra and Tan, Li Hong and Tay, Eileen and Hai, Ronald Toh Kuan and Kwek, Perlyn Zekui and Wong, Mei Yee and Raman, Deepika and Ang, Qi An and Manoharan, Vithya and Vuddagiri, Susmitha and Dawson, Monique Danielle and Tan, Alison and Joy, Joma Kanikadu and Gan, Bong Hwa and Low, Choon Bing and Xu, Haoying and Lim, Siew Pheng and Hentze, Hannes and Cherian, Joseph and Tan, Chong Teik and Ang, Jackie and Ethirajulu, Kantharaj and Foo, Klement and Singh, Inderjeet and Xu, Weijun},
title = {In Silico‐Enabled Discovery and Development of Potent and Selective CDK11 Inhibitors},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {6},
doi = {10.1002/cmdc.202500882}
}
EUVIMED